Last reviewed · How we verify
Olvi-Vec
At a glance
| Generic name | Olvi-Vec |
|---|---|
| Sponsor | Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC (PHASE1, PHASE2)
- Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olvi-Vec CI brief — competitive landscape report
- Olvi-Vec updates RSS · CI watch RSS
- Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. portfolio CI